Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 70.11B 9.38B 8.57B 7.82B 14.74B 983B 15.2B 103B 41.19B 524B 39.25B 38.4B 1,656B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 70.31B 9.4B 8.59B 7.85B 14.78B 986B 15.25B 104B 41.31B 526B 39.36B 38.51B 1,660B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/04/21	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/02/20	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/02/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/01/20	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/11/19	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/11/19	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
14/11/19	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
13/11/19	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/10/19	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/06/21	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/02/20	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
30/01/20	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
28/01/20	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
28/01/20	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
ELI LILLY AND COMPANY	-0.27%	-3.96%	+45.23%	+128.74%	1,216B
JOHNSON & JOHNSON	+0.94%	+0.74%	+47.19%	+81.42%	656B
ABBVIE INC.	+0.82%	-1.67%	+32.38%	+105.35%	509B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	384B
MERCK & CO., INC.	-0.20%	-2.01%	+70.81%	+40.43%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	311B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	293B
AMGEN INC.	+0.27%	-1.00%	+46.19%	+69.10%	249B
GILEAD SCIENCES, INC.	-0.11%	-1.78%	+35.86%	+106.62%	208B
Average	-0.15%	+0.54%	+40.44%	+76.64%	418.94B
Weighted average by Cap.	-0.08%	+0.03%	+42.30%	+88.54%

	2017	2018
Net sales	30.17M 202M 27.06M 24.73M 22.57M 42.53M 2.84B 43.87M 298M 119M 1.51B 113M 111M 4.78B	39.49M 265M 35.42M 32.37M 29.55M 55.68M 3.71B 57.43M 390M 156M 1.98B 148M 145M 6.25B
Net income	-9.54M -63.98M -8.56M -7.82M -7.14M -13.45M -897M -13.88M -94.28M -37.59M -479M -35.82M -35.05M -1.51B	-5.28M -35.44M -4.74M -4.33M -3.95M -7.45M -497M -7.69M -52.22M -20.82M -265M -19.84M -19.41M -837M
Net Debt	18.05M 121M 16.19M 14.8M 13.51M 25.45M 1.7B 26.25M 178M 71.12M 905M 67.76M 66.3M 2.86B	29.38M 197M 26.36M 24.09M 21.99M 41.43M 2.76B 42.73M 290M 116M 1.47B 110M 108M 4.65B